Director and 10% owner Jorey Chernett filed a Form 4 with the SEC on November 10, 2026, disclosing a series of common stock and call option transactions in Starling Oncology, Inc. (NASDAQ:STLN) spanning November 6 through November 10, 2026.
Key Highlights
- Large share sale: Chernett disposed of 2,851,061 shares of common stock on November 6, 2026, at a weighted average price of $3.99, with individual sale prices ranging from $3.38 to $5.21.
- Subsequent purchase: On November 9, 2026, Chernett acquired 48,294 shares at a weighted average price of $3.65, with individual purchase prices ranging from $3.53 to $3.91.
- Resulting ownership: Following both transactions, Chernett directly beneficially owned 7,858,091 shares of common stock.
- Call options acquired: Chernett purchased four series of call options across the three transaction dates, covering an aggregate of 29,500 contracts tied to 2,950,000 underlying shares of common stock.
- Short-swing profit disclosure: The filing states the reported transactions "are matchable transactions subject to Section 16(b)" and that Chernett "has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer."
Chernett's November 2026 Transactions at Starling Oncology
According to the filing, Jorey Chernett, identified as a director and 10% owner of Starling Oncology, Inc., sold 2,851,061 shares of common stock on November 6, 2026, at a weighted average price of $3.99 per share. The filing notes this was a weighted average across multiple transactions ranging from $3.38 to $5.21 per share. Following that sale, Chernett's direct beneficial ownership stood at 7,809,797 shares.
Three days later, on November 9, 2026, Chernett purchased 48,294 shares of common stock at a weighted average price of $3.65, across a range of $3.53 to $3.91 per share, bringing directly held shares to 7,858,091. In addition to the common stock transactions, Chernett acquired call options across three dates: 10,000 contracts of STLN 20NOV26 $4C at $0.075 per contract on November 6; 5,000 contracts of STLN 19FEB27 $4C at $0.40 per contract on November 6; 7,500 contracts of STLN 19FEB27 $5C at a weighted average of $0.5357 on November 9; and 7,000 contracts of STLN 21MAY27 $5C at $0.67 per contract on November 10, 2026. Each series carries an exercise price of either $4.00 or $5.00 per share of common stock.
The filing discloses that Chernett has calculated a short-swing profit arising from these matchable transactions under Section 16(b) of the Securities Exchange Act of 1934, and states an intent to disgorge that profit to the issuer. Chernett has also undertaken to provide, upon request, full detail on shares or options transacted at each individual price.
What Was Disclosed
The Form 4 covers common stock disposals and acquisitions, plus purchases of four series of call options, by director and 10% owner Jorey Chernett in Starling Oncology, Inc. (NASDAQ:STLN) between November 6 and November 10, 2026, along with a stated intent to disgorge a calculated short-swing profit to the issuer.



Please wait processing your request...